----Thirty-four hyperthyroid patients were divided into four groups : placebo, carteolol (20 mg/day), indenolol (60 mg/day) and metoprolol (120 mg/day) groups. The heart rate was determined before and two weeks after the treatment with each drug. Serum levels of T4, T3 and rT3 were measured before, and one and two weeks after the treatment. Both indenolol and metoprolol significantly reduced the heart rate (p <0.01 and p <0.05, respectively), whereas carteolol was ineffective. Carteolol significantly decreased T4 from 23.4± 4.4 ,u g/ 100 ml to 20.1 + 3.2,u g/ 100 ml (p < 0.01) in one week and to 20.0±3.7,ug/100 ml (p <0.01) in two weeks. T3 and rT3 were also decreased significantly (p <0.05 and p <0.01, respectively) two weeks after the treatment with carteolol. After two weeks of indenolol treatment, T4 was decreased significantly from 26.2±8.5 u g/ 100 ml to 23.9±8.2 p g/100 ml (p < 0.05) and T3 from 789+391ng/100 ml to 592+340 ng/100 ml (p <0.02). Metoprolol had no effect on serum thyroid hormone levels. The decrease in the serum level of thyroid hormones by carteolol and indenolol but not by metoprolol in patients with hyperthyroidism would be due to the blockade of f2-adrenoreceptors concerning with thyroid hormone secretion.
We studied the effect of two non-selective /3-adrenoreceptor blockers ; carteolol with strong intrinsic sympathomimetic activity (ISA) and no membrane stabilizing activity (MSA) (Nakagawa et al. 1974 ) and indenolol with MSA and weak ISA (Tachikawa and Takenaka 1973) , and one /31-selective adrenoreceptor blocker, metoprolol without ISA and MSA (Frishman 1981) , on the heart rate and serum thyroid hormones in patients of hyperthyroidism.
METHODS
The present study was carried out in 34 in-patients with Graves' disease. The diagnosis was confirmed by elevated levels of T4 and T3 and increased thyroidal uptake of radioiodine.
The patients ranging in age from 23 to 65 years, and including 11 males were randomly divided into four groups : Placebo group (n=8), carteolol group (10 mg b.i.d., n=9), indenolol group (20 mg t.i.d., n=8) and metoprolol group (40 mg t.i.d., n=9).
Doses used for each drug were those administered usually to patients in Japan.
Each drug was prescribed by a double-blind technique. Initially, serum specimens for determination of T4, T3 and rT3 were collected at 9 : 00 a.m. after an overnight fast, and then the administration of /3-adrenoreceptor blockers or placebo was started.
One and two weeks after the treatment, blood was withdrawn at 9 : 00 a.m. one hour after the final medication. Two weeks after the start of the treatment, clinical examinations were performed.
Any other medications were not used in this period.
The serum concentrations of T4 (Sakurada et al. 1976 ), T3 (Sakurada et al. 1973 ) and rT3 (Yoshida et al. 1983) were determined by radioimmunoassay with commercial kits (T4-RIA, T3-RIA and rT3-RIA, Dinabbot RI Lab., Japan). The normal ranges were : T4, 5-12.5,ug/100 ml ; T3, 70-180 ng/100 ml and rT3, 22-35 ng/100 ml.
The blood pressure before and after the treatment with /3-adrenoreceptor blockers was measured by the same doctor in each individual patient with conventional sphygmomanometer. Diastolic pressure was measured by the fifth sound. The heart rate was calculated from the mean values of five R-R intervals on ECG.
Student's paired t-test was used to assess differences between the values before and after the treatment.
RESULTS
The heart rate, cardiothoracic ratio and blood pressure before and two weeks after the treatment are summarized in Table 1 .
There was no change in any parameter during the treatment with carteolol. Both indenolol and metoprolol significantly reduced the heart rate (p <0.01 and p <0.05, respectively). Though a slight increase in cardiothoracic ratio was found during the treatments with indenolol and metoprolol, it was not statistically significant (p >0.9 and p >0.7). Indenolol significantly reduced the diastolic blood pressure (p <0.05), whereas metoprolol reduced the systolic blood pressure (p <0.02).
The changes in serum thyroid hormones during the treatments are shown in Table 2 .
The carteolol treatment caused a significant reduction in serum T4 from 23.4 + 4.4 ,u g/ 100 ml to 20.1±3.2 jig/l00 ml (p<0.01) in one week and to 20.0± 3.7 ,u g/ 100 ml (p <0.01) in two weeks. The concentrations of serum T3 and rT3 were also decreased (p <0.05 and p <0.01, respectively) two weeks after the treatment with carteolol. The treatment with indenolol for two weeks resulted in decreases in serum T4 from 26.2±8.5 p g/ 100 ml to 23.9±8.2 1u g/ 100 ml (p <0.05) and serum T3 from 789+391 ng/100 ml to 592+340 ng/100 ml (p <0.02), but serum rT3 was unchanged. In the metoprolol treatment there was no significant change in any of the three thyroid hormones. 
DISCUSSION
In the present study, we investigated the effect of the three f3-adrenoreceptor blockers with different properties (Table 3) on the heart rate and serum thyroid hormones in hyperthyroid patients.
Carteolol, a non-selective /3-adrenoreceptor blocker with ISA (Nakagawa et al. 1974), was inferior to indenolol and metoprolol in reducing the heart rate. Indenolol, also a non-selective fl-adrenoreceptor blocker, has a weak ISA and MSA (Tachikawa and Takenaka 1973) . Metoprolol is a selective R1-adrenoreceptor blocker with neither ISA nor MSA (Frishman 1981) . Practolol (Murchison et al. 1976 ) and oxprenolol (Jones et al. 1981 ) possess some ISA which may explain why these drugs are less effective in reducing the heart rate than other /3-adrenoreceptor blockers without ISA. Although indenolol possesses a weak ISA, it was effective for the amelioration of thyrotoxic tachycardia because of its MSA in addition to its /3-adrenoreceptor blocking activity.
It has been amply confirmed that propranolol causes a significant reduction in serum T3 and a concomitant increase in serum rT3 (Verhoeven et al. 1977 ; Kallner et al. 1978; Saunders et al. 1978) , although its effect on thyroxine is less consistent (Kallner et al 1978; Murchison et al. 1979 ). It was reported that propranolol has no direct effect on thyroid functions, as measured by radioiodine uptake and serum protein-bound-iodine (Wartofsky et al. 1975 ). Several authors (Heyma et al. 1980; Nilsson et al. 1980 ) suggest that propranolol-induced changes in T3 and rT3 concentrations might be due to MSA (Heyma et al. 1980) or direct inhibition of the enzyme responsible for the T4 monodeiodionation to T3 (Nilsson et al. 1980) . It is also possible that the changes might result from f32-adrenoreceptor blockade, since some authors have noticed a decrease in T3 during propranolol treatment, but no changes during the administration of selective f31-adrenoreceptor blockers such as atenolol (Nilsson et al. 1979 ), practolol (Murchison et al. 1976) , and metoprolol (Murchison et al. 1979 ; Nilsson et al. TABLE 3 . Pharmacological properties and effect on serum thyroid hormones of carteolol, indenolol and metoprolol 1980). Melander et al. (1975) investigated the influence on thyroid hormone secretion of the non-selective /3-adrenoreceptor stimulant, isoproterenol, the selective f,-adrenoreceptor stimulant, 1-isopropylamino-3-(2-thiazoloxy)-2-propanol (ITP) and the selective f32-adrenoreceptor stimulant, terbutaline in mice, observing the colloid droplet formation and PB131 I. Isoproterenol and terbutaline induced colloid droplet formation and increased blood radioiodine levels, whereas ITP was ineffective. The responses to isoproterenol and terbutaline were abolished or reduced by pretreatment with (-)-propranolol but not by (+ )-propranolol or phentolamine.
These results suggested that the secretion of thyroid hormone could be influenced through the mediation by /32-adrenoreceptors. This mechanism was confirmed by Ahren and Rerup (1983) .
In the present study, treatment with carteolol caused a significant reduction in serum T4, T3 and rT3. Indenolol also decreased both serum T4 and T3 but in this respect it was less effective than carteolol. Serum rT3 was unchanged by Indenolol treatment. No influence of metoprolol on serum thyroid hormones was observed. These results suggest that the reduction of serum thyroid hormones would result from 1-2-adrenoreceptor blockade.
Concerning the potency of f3-adrenoreceptor blockers, carteolol is about ten times as potent as propranolol (Nakagawa et al. 1974 ) and Indenolol (Tachikawa and Takenaka 1973) . Other non-specific /3-adrenoreceptor blockers, oxprenolol (Jones et al. 1981 ) and sotalol (Wahlberg et al. 1976 ), which had been reported to be ineffective on the serum levels of thyroid hormones, were less potent than propranolol (Frishman 1979 ). The significant decrease in serum thyroid hormones induced by the treatment with carteolol would be attributed to its stronger /3-adrenoreceptor blocking activity.
